Nautilus Shifts Roadmap to Proteoforms, Delays Broadscale
The company booked $0.2 million of second-quarter revenue and said Voyager pre-orders are expected in early 2027.
Nautilus Biotechnology (NAUT), a development-stage life sciences company building a single-molecule proteome analysis platform, recognized its first revenue in the second quarter of 2026 and said it is shifting resources to accelerate proteoform applications rather than a 2027 broadscale consumable kit.
Revenue was $0.2 million, comprising $180 thousand of grant revenue from The Michael J. Fox Foundation supporting alpha-synuclein proteoform assay development and $10 thousand of service revenue from the first Iterative Mapping Early Access Program customer. The year-ago quarter had no revenue.
The company said customer enthusiasm for proteoform applications has grown since the Iterative Mapping Early Access program launched in the first quarter, including additional customer-requested targets. It is selecting and advancing its first oncology proteoform, AKT1, with expected Early Access availability in late 2026. The commercial organization grew to three team members, including the previously announced VP of Global Sales.
Under the realigned roadmap, Voyager Platform pre-orders are expected in early 2027, with instrument shipments beginning in mid 2027. Tau Proteoforms Assay consumable kits and AKT1 kits are expected in general availability in mid 2027. A second oncology proteoforms assay is also expected in mid 2027, with a third oncology assay and further pipeline expansion in late 2027. Chief Executive Officer Sujal Patel said the shift is funded through reallocation rather than incremental spend and does not change the company’s broader financial assumptions.
Broadscale moved the other way. In the second quarter, Nautilus completed testing and determined that assay configuration changes do not sufficiently improve probe candidate performance to support a 2027 general availability of a broadscale consumable kit at target specifications. It said it has identified key improvement areas, begun development work, and will report a commercial timeline for the Broadscale Assay at a future date.
Operating expenses were $15.9 million, down $1.2 million or 7% from $17.1 million a year earlier, after a $2.7 million or 14% year-over-year decline in the first quarter. The company attributed the latest drop to lower salaries and related benefits, stock-based compensation, and facilities costs. Research and development expense was $9.6 million and selling, general and administrative expense was $6.3 million.
Net loss was $14.5 million, or $0.11 a share, compared with a $15.0 million loss, or $0.12 a share, a year earlier. Cost of service revenue was $15 thousand. Interest income was $1.3 million.
Cash, cash equivalents, and investments were $129.2 million as of June 30, 2026, down from $143.4 million as of March 31, 2026. Cash and cash equivalents were $13.2 million, short-term investments $70.9 million, and long-term investments $45.2 million. Total assets were $163.6 million.
Patel said the second quarter reinforced the company’s view that proteoforms deliver biological resolution Nautilus is positioned to deliver, and that the realignment puts the company on a more direct path to becoming a commercial company. The company said it plans to concurrently develop expanded proteoform capabilities, including lower sample input, additional sample types, and increased proteoform depth.
Stronger demand supports expansion as pricing diverges